Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape ; volume:43 ; number:1 ; day:6 ; month:2 ; year:2024 ; pages:1-5 ; date:12.2024
Journal of experimental & clinical cancer research ; 43, Heft 1 (6.2.2024), 1-5, 12.2024
- Creator
-
Scafetta, Giorgia
D’Alessandria, Calogero
Bartolazzi, Armando
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-024-02968-2
- URN
-
urn:nbn:de:101:1-2024041511001156642735
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Scafetta, Giorgia
- D’Alessandria, Calogero
- Bartolazzi, Armando
- SpringerLink (Online service)
Other Objects (12)
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Acquired mechanisms of immune escape in cancer following immunotherapy
STATISTICAL METHOD TO OVERCOME OVERFITTING ISSUE IN RATIONAL FUNCTION MODELS
Immunotherapy in endometrial cancer: rationale, practice and perspectives
Viral escape from NK‐cell‐mediated immunosurveillance: A lesson for cancer immunotherapy?
CAR‐Aptamers Enable Traceless Enrichment and Monitoring of CAR‐Positive Cells and Overcome Tumor Immune Escape
Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma
Prosaposin hyperglycosylation: a novel tumor immune escape mechanism and implications for cancer immunotherapy
Frequency-dependent selection of neoantigens fosters tumor immune escape and predicts immunotherapy response
A Synthetic Galectin Mimic
A Synthetic Galectin Mimic
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Acquired mechanisms of immune escape in cancer following immunotherapy
STATISTICAL METHOD TO OVERCOME OVERFITTING ISSUE IN RATIONAL FUNCTION MODELS
Immunotherapy in endometrial cancer: rationale, practice and perspectives
Viral escape from NK‐cell‐mediated immunosurveillance: A lesson for cancer immunotherapy?
CAR‐Aptamers Enable Traceless Enrichment and Monitoring of CAR‐Positive Cells and Overcome Tumor Immune Escape
Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma
Prosaposin hyperglycosylation: a novel tumor immune escape mechanism and implications for cancer immunotherapy
Frequency-dependent selection of neoantigens fosters tumor immune escape and predicts immunotherapy response
A Synthetic Galectin Mimic
A Synthetic Galectin Mimic
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Acquired mechanisms of immune escape in cancer following immunotherapy
STATISTICAL METHOD TO OVERCOME OVERFITTING ISSUE IN RATIONAL FUNCTION MODELS
Immunotherapy in endometrial cancer: rationale, practice and perspectives
Viral escape from NK‐cell‐mediated immunosurveillance: A lesson for cancer immunotherapy?
CAR‐Aptamers Enable Traceless Enrichment and Monitoring of CAR‐Positive Cells and Overcome Tumor Immune Escape
Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma
Prosaposin hyperglycosylation: a novel tumor immune escape mechanism and implications for cancer immunotherapy
Frequency-dependent selection of neoantigens fosters tumor immune escape and predicts immunotherapy response
A Synthetic Galectin Mimic
A Synthetic Galectin Mimic